隐源性卒中合并卵圆孔未闭患者的抗栓治疗:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项随机对照试验共1720例未行介入封堵的隐源性卒中或TIA合并卵圆孔未闭患者,比较抗凝与抗血小板治疗。结果显示抗凝组卒中复发率数值上较低(HR 0.68,95%CI 0.32-1.48),大出血率数值上较高(HR 1.61,95%CI 0.72-3.59),复合终点无差异(OR 1.05,95%CI 0.65-1.70),均无统计学意义。
要点
- 抗凝与抗血小板在卒中复发、大出血及复合终点上均无显著差异。
- 抗凝组卒中复发率数值更低,但置信区间宽,不能排除大幅获益。
- 抗凝组大出血率数值更高,但差异无统计学意义。
核心结论
- 不能排除抗凝治疗较抗血小板治疗大幅降低卒中复发风险,且大出血无显著差异。
- 需要一项有足够把握度的非维生素K拮抗剂 vs 阿司匹林随机对照试验。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed至2019年7月16日,纳入5项随机对照试验共1720例患者,平均随访2.3±0.5年。
- 比较未行经皮封堵的隐源性卒中或TIA合并卵圆孔未闭患者的抗凝与抗血小板治疗。
- 采用三种随机效应模型:基于逆方差法的Sidik和Jonkman异质性估计模型、Hartung和Knapp严格模型、以及假设中到大研究间方差的贝叶斯模型。
主要发现
- 卒中复发率:抗凝组1.73/100患者年 vs 抗血小板组2.39/100患者年(HR 0.68;95%CI 0.32-1.48,Sidik和Jonkman估计)。
- 大出血率:抗凝组1.16/100患者年 vs 抗血小板组0.68/100患者年(HR 1.61;95%CI 0.72-3.59,Sidik和Jonkman估计)。
- 复合终点(卒中复发或大出血):抗凝组52例 vs 抗血小板组54例(OR 1.05;95%CI 0.65-1.70,Sidik和Jonkman估计)。
临床怎么用
- 对于未行卵圆孔未闭封堵的隐源性卒中或TIA患者,抗凝与抗血小板治疗的选择应个体化。
- 现有证据未显示任一策略在卒中复发或大出血方面有显著优势,临床决策需权衡获益与风险。
局限性
- 纳入研究数量少(5项),总样本量有限(1720例),随访时间较短(平均2.3年)。
- 置信区间宽,不能排除抗凝治疗的大幅获益或显著危害。
- 未针对非维生素K拮抗剂与阿司匹林进行直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- It is unclear whether treatment with anticoagulants or antiplatelets is the optimal strategy in patients with stroke or transient ischemic attack of undetermined cause and patent foramen ovale that is not percutaneously closed. We aimed to perform a systematic review and meta-analysis of randomized controlled trials to compare anticoagulant or antiplatelet treatment in this population. Methods- We searched PubMed until July 16, 2019 for trials comparing anticoagulants and antiplatelet treatment in patients with stroke/transient ischemic attack and medically treated patent foramen ovale using the terms: "cryptogenic or embolic stroke of undetermined source" and "stroke or cerebrovascular accident or transient ischemic attack" and "patent foramen ovale or patent foramen ovale or paradoxical embolism" and "trial or study" and "antithrombotic or anticoagulant or antiplatelet." The outcomes assessed were stroke recurrence, major bleeding, and the composite end point of stroke recurrence or major bleeding. We used 3 random-effects models: (1) a reference model based on the inverse variance method with the Sidik and Jonkman heterogeneity estimator; (2) a strict model, implementing the Hartung and Knapp method; and (3) a commonly used Bayesian model with a prior that assumes moderate to large between-study variance. Results- Among 112 articles identified in the literature search, 5 randomized controlled trials were included in the meta-analysis (1720 patients, mean follow-up 2.3±0.5 years). Stroke recurrence occurred at a rate of 1.73 per 100 patient-years in anticoagulant-assigned patients and 2.39 in antiplatelet-assigned patients (hazard ratio, 0.68; 95% CI, 0.32-1.48 for the Sidik and Jonkman estimator). Major bleeding occurred at a rate of 1.16 per 100 patient-years in anticoagulant-assigned patients and 0.68 in antiplatelet-assigned patients (hazard ratio, 1.61; 95% CI, 0.72-3.59 for the Sidik and Jonkman estimator). The composite outcome occurred in 52 anticoagulant-assigned and 54 antiplatelet-assigned patients (odds ratio, 1.05; 95% CI, 0.65-1.70 for the Sidik and Jonkman estimator). Conclusions- We cannot exclude a large reduction of stroke recurrence in anticoagulant-assigned patients compared with antiplatelet-assigned, without significant differences in major bleeding. An adequately powered randomized controlled trial of a non-vitamin K antagonist versus aspirin is warranted.
引用
- Sagris D, Georgiopoulos G, Perlepe K, et al. Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis. Stroke. 2019. PMID: 31547797. doi:10.1161/STROKEAHA.119.026512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。